Cargando…

Arguments in favour of remdesivir for treating SARS-CoV-2 infections

Detalles Bibliográficos
Autores principales:	Ko, Wen-Chien, Rolain, Jean-Marc, Lee, Nan-Yao, Chen, Po-Lin, Huang, Ching-Tai, Lee, Ping-Ing, Hsueh, Po-Ren
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier B.V. and International Society of Chemotherapy. 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7135364/ https://www.ncbi.nlm.nih.gov/pubmed/32147516 http://dx.doi.org/10.1016/j.ijantimicag.2020.105933

Ejemplares similares

An Argument in Favour of Tobacco
Publicado: (1893)

Long COVID: An inevitable sequela of SARS-CoV-2 infection
por: Lai, Chih-Cheng, et al.
Publicado: (2023)

Emerging threats from zoonotic coronaviruses-from SARS and MERS to 2019-nCoV
por: Lee, Ping-Ing, et al.
Publicado: (2020)

Subspecialisation within infection prevention and control: the argument in favour
por: Weinbren, Michael, et al.
Publicado: (2021)

The Notification of Puerperal Fever: Some Arguments in Favour of Its Abolition
Publicado: (1913)

SARS-CoV-2 and COVID-19
por: Sheng, Wang-Huei, et al.
Publicado: (2020)

Remarks on Mr. Bellingham's Case of Hydrophobia, with Arguments in Favour of Bleeding in That Disease
por: Key, Thomas
Publicado: (1815)

SARS-COV-2 as an artificial creation: scientific arguments and counterarguments
por: Yee, Shermaine, et al.
Publicado: (2021)

Multisystem inflammatory syndrome in children: A dysregulated autoimmune disorder following COVID-19
por: Lee, Ping-Ing, et al.
Publicado: (2023)

Intermittent preventive therapy for malaria: arguments in favour of artesunate and sulphamethoxypyrazine - pyrimethamine combination
por: Jansen, Frans Herwig
Publicado: (2011)

Extra-respiratory manifestations of COVID-19
por: Lai, Chih-Cheng, et al.
Publicado: (2020)

A case of COVID-19 and pneumonia returning from Macau in Taiwan: Clinical course and anti-SARS-CoV-2 IgG dynamic
por: Lee, Nan-Yao, et al.
Publicado: (2020)

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges
por: Lai, Chih-Cheng, et al.
Publicado: (2020)

Nanoparticles in the Treatment of Infections Caused by Multidrug-Resistant Organisms
por: Lee, Nan-Yao, et al.
Publicado: (2019)

Dignity, conscience and religious pluralism in healthcare: An argument for a presumption in favour of respect for religious belief
por: Kirchhoffer, David G.
Publicado: (2022)

Evolving reporting criteria of COVID-19 in Taiwan during the epidemic
por: Huang, Yhu-Chering, et al.
Publicado: (2020)

Treatment options for COVID-19: The reality and challenges
por: Jean, Shio-Shin, et al.
Publicado: (2020)

How Taiwan has responded to COVID-19 and how COVID-19 has affected Taiwan, 2020–2022
por: Lai, Chih-Cheng, et al.
Publicado: (2023)

The impact of COVID-19 preventative measures on airborne/droplet-transmitted infectious diseases in Taiwan
por: Lai, Chih-Cheng, et al.
Publicado: (2021)

The impact of the coronavirus disease 2019 epidemic on notifiable infectious diseases in Taiwan: A database analysis
por: Lai, Chih-Cheng, et al.
Publicado: (2021)

Monkeypox: An emerging global threat during the COVID-19 pandemic
por: Lai, Chih-Cheng, et al.
Publicado: (2022)

COVID-19 Therapeutic and Prevention
por: Raoult, Didier, et al.
Publicado: (2020)

Simeprevir Potently Suppresses SARS-CoV-2 Replication and Synergizes with Remdesivir
por: Lo, Ho Sing, et al.
Publicado: (2021)

On the origin of SARS-CoV-2—The blind watchmaker argument
por: Wu, Chung-I, et al.
Publicado: (2021)

A Review of Treatment of Coronavirus Disease 2019 (COVID-19): Therapeutic Repurposing and Unmet Clinical Needs
por: Chen, Po-Lin, et al.
Publicado: (2020)

Remdesivir use in the coronavirus disease 2019 pandemic: A mini-review
por: Yang, Chih-Jen, et al.
Publicado: (2021)

Clostridium difficile Bacteremia, Taiwan1
por: Lee, Nan-Yao, et al.
Publicado: (2010)

Are children less susceptible to COVID-19?
por: Lee, Ping-Ing, et al.
Publicado: (2020)

Therapeutic Efficacy and Outcomes of Remdesivir versus Remdesivir with Tocilizumab in Severe SARS-CoV-2 Infection
por: Vulturar, Damiana-Maria, et al.
Publicado: (2022)

Dynamics of anti-SARS-Cov-2 IgM and IgG antibodies among COVID-19 patients
por: Lee, Yu-Lin, et al.
Publicado: (2020)

Remdesivir-associated bradycardia
por: Ching, Patrick R, et al.
Publicado: (2021)

A case of transient existence of SARS-CoV-2 RNA in the respiratory tract with the absence of anti-SARS-CoV-2 antibody response
por: Lin, Yi-Chun, et al.
Publicado: (2020)

Remdesivir MD Simulations Suggest a More Favourable Binding to SARS-CoV-2 RNA Dependent RNA Polymerase Mutant P323L Than Wild-Type
por: Mohammad, Anwar, et al.
Publicado: (2021)

How to Keep COVID-19 at Bay: A Taiwanese Perspective
por: Lai, Chih-Cheng, et al.
Publicado: (2021)

Remdesivir and Cyclosporine Synergistically Inhibit the Human Coronaviruses OC43 and SARS-CoV-2
por: Hsu, Hsing-Yu, et al.
Publicado: (2021)

Four point-of-care lateral flow immunoassays for diagnosis of COVID-19 and for assessing dynamics of antibody responses to SARS-CoV-2
por: Wu, Jhong-Lin, et al.
Publicado: (2020)

Viable SARS-CoV-2 shedding under remdesivir and dexamethasone treatment
por: Yoon, Jin Gu, et al.
Publicado: (2022)

Early experience with remdesivir in SARS-CoV-2 pneumonia
por: Durante-Mangoni, Emanuele, et al.
Publicado: (2020)

Contre Sars-CoV-2, brequinar ou remdesivir ?
por: Manus, Jean-Marie
Publicado: (2021)

Remdesivir therapy associated with Bradycardia in SARS‐CoV2
por: Kumar, Sabina, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1vr167f61t4oo9p8b9evv1aiuk